Craif and Chiba University Presents Study Result Regarding Early Detection of Ovarian Cancer Using Urine at the “ESMO Congress 2021”

Craif (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”)  is pleased to announce that it presented a joint study result regarding ovarian cancer with Shinichi Tate, Associate Professor at Chiba University Hospital, at “ESMO Congress 2021,” held online in Paris, France from 16th September to 21st September. With the result of this study, Craif will aim for implementation of an ovarian cancer test using urinary miRNA.

■ Joint Study with Chiba University
Chiba University and Craif are conducting a clinical study to analyze urinary miRNA in ovarian cancer patients using microfluidic nanowire devices from 2019. In this study, the following results were reported: 1) many useful ovarian cancer biomarker candidates were identified by urinary miRNA analysis, 2) by conducting assessment of urinary miRNA expression by RT-qPCR method, we successfully detected early stage ovarian cancer with high accuracy (AUC 0.98), 3) this method was found to be effective in detecting stage 1 ovarian cancer with high sensitivity.

■ Outline of “ESMO Congress 2021”
ESMO is the most influential oncology platform designed in Europe for clinicians, researchers, patient advocates, journalists and healthcare industry representatives all around the world. In 2020, with the unprecedented environment regarding COVID19, a comprehensive, scientific and educational program was conducted virtually. ESMO aims to deliver new data in oncology to the world in real time, and to promote professional education in oncology.

The ESMO Congress 2021 will showcase the latest advances in cancer treatment and provide an opportunity for delegates from all over the world to exchange ideas and opinions in an interactive environment.

[Dates] 16th September – 21st September, 2021
[Venue] Paris/France (online), Paris Expo Porte des Versailles
[Official Website]